Showing 1 - 10 of 1,623
Prescription drugs are the highest single cost component for employees’ benefits packages in Canada. While industry literature considers cost-containment for prescription drug costs to be a priority for insurers and employers, the implementation of cost-containment measures for private drug...
Persistent link: https://www.econbiz.de/10011190164
This paper examines the prospects for reform of Russia’s healthcare system. It begins by exploring a number of fundamental imbalances that characterise the current half-reformed system of healthcare provision before going on to assess the government’s plans for going ahead with healthcare...
Persistent link: https://www.econbiz.de/10005046136
In order to contain expenditures for pharmaceuticals, the latest healthcare reforms have focused on decentralising …
Persistent link: https://www.econbiz.de/10010670125
Persistent link: https://www.econbiz.de/10010677771
Die private (PKV) und die gesetzliche Krankenversicherung (GKV) werden durch die so genannte Friedensgrenze getrennt …
Persistent link: https://www.econbiz.de/10010980899
Die effektiv zu zahlende Prämie bestimmt sich in der Privaten Krankenversicherung als Summe aus Tarifbeiträgen … Selbsttragung in der Krankenversicherung die finanziellen Folgen der Änderung eines realen Beitragsrückerstattungssystems untersucht …
Persistent link: https://www.econbiz.de/10010984671
Persistent link: https://www.econbiz.de/10005037333
pharmaceuticals. The paper studies the export performance of 177 Indian pharmaceutical firms for the post- liberalization period 1991 …
Persistent link: https://www.econbiz.de/10005518310
THE DRUGS AND COSMETICS (AMENDMENT) BILL, 2005 A Bill further to amend the Drugs and Cosmetics Act, 1940. Under examination with the Committee on Health and Family Welfare On adulterated and spurious drugs
Persistent link: https://www.econbiz.de/10005528115
The Task Force recommends that price regulation should be on the basis of ‘Essentiality’ of the drug and it should be applied only to formulations and not to upstream products, such as bulk drugs. No effort should be made to impose a uniform price, and only a ceiling price should be...
Persistent link: https://www.econbiz.de/10005528148